Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity.

The antineoplastic drug doxorubicin is capable of generating a variety of free radical species in subcellular systems and this capacity has been considered critical for its antitumor action. However, for most tumor cell lines this mechanism of cytotoxicity does not appear to play a major role. Free radical-independent cytotoxicity mechanisms, taking place in the nuclear compartment of the cell, may more likely be involved in the antitumor effect of doxorubicin.

[1]  H. Nohl,et al.  OH.-generation by adriamycin semiquinone and H2O2; an explanation for the cardiotoxicity of anthracycline antibiotics. , 1983, Biochemical and biophysical research communications.

[2]  J. Zweier,et al.  Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen. , 1985, The Journal of biological chemistry.

[3]  R. Erttmann,et al.  Pharmacokinetics of doxorubicin in man: dose and schedule dependence , 2004, Journal of Cancer Research and Clinical Oncology.

[4]  E. Mimnaugh,et al.  Enzymatic activation and binding of adriamycin to nuclear DNA. , 1984, Cancer research.

[5]  N. Bachur,et al.  Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. , 1977, Molecular pharmacology.

[6]  B. Sinha,et al.  Role of one-electron and two-electron reduction products of adriamycin and daunomycin in deoxyribonucleic acid binding. , 1981, Biochemical pharmacology.

[7]  E. Mimnaugh,et al.  Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. , 1985, Biochemical pharmacology.

[8]  G. Batist,et al.  Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. , 1987, Biochemistry.

[9]  M. Israel,et al.  Two mechanisms of adriamycin-DNA interaction in L1210 cells. , 1984, Biochemical pharmacology.

[10]  E. Porta,et al.  Acute adriamycin cardiotoxicity in rats. , 1983, Research communications in chemical pathology and pharmacology.

[11]  V. Malatesta,et al.  Role of daunosamine and hydroxyacetyl side chain in reaction with iron and lipid peroxidation by anthracyclines. , 1988, Journal of the National Cancer Institute.

[12]  G. Powis,et al.  Pulse radiolysis studies of antitumor quinones: radical lifetimes, reactivity with oxygen, and one-electron reduction potentials. , 1981, Archives of biochemistry and biophysics.

[13]  N. Bachur,et al.  Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. , 1983, Archives of biochemistry and biophysics.

[14]  J. Zweier.  Iron-mediated formation of an oxidized adriamycin free radical. , 1985, Biochimica et biophysica acta.

[15]  B. Carr,et al.  Cell surface-mediated cytotoxicity of polymer-bound Adriamycin against drug-resistant hepatocytes. , 1983, Cancer research.

[16]  Z. Tökés,et al.  Novel mode of cytotoxicity obtained by coupling inactive anthracycline to a polymer. , 1984, Biochemical pharmacology.

[17]  A. Riva,et al.  Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei. , 1987, Cancer research.

[18]  Z. Kawakami,et al.  Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione. , 1986, Cancer research.

[19]  R. Mason,et al.  Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. , 1980, Biochimica et biophysica acta.

[20]  R. Kramer,et al.  Role of the glutathione redox cycle in acquired and de novo multidrug resistance. , 1988, Science.

[21]  L. Gianni,et al.  Thiol-dependent DNA damage produced by anthracycline-iron complexes. The structure-activity relationships and molecular mechanisms. , 1985, Molecular pharmacology.

[22]  L. Gianni,et al.  Oxidative destruction of DNA by the adriamycin-iron complex. , 1984, Biochemistry.

[23]  J. Lankelma,et al.  Correlation of multidrug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells , 1989 .

[24]  G. Goldenberg,et al.  Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. , 1989, Cancer research.

[25]  J. Zweier.  Reduction of O2 by iron-adriamycin. , 1984, The Journal of biological chemistry.

[26]  M. Shamoto,et al.  Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. , 1982, Cancer research.

[27]  S. Doglia,et al.  Quantitative study of doxorubicin in living cell nuclei by microspectrofluorometry. , 1988, Biochimica et biophysica acta.

[28]  J. Doroshow,et al.  Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. , 1981, The Journal of clinical investigation.

[29]  J. Gutteridge,et al.  Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron (III) complex. , 1984, Biochemical pharmacology.

[30]  E. Mimnaugh,et al.  Stimulation of mouse heart and liver microsomal lipid peroxidation by anthracycline anticancer drugs: characterization and effects of reactive oxygen scavengers. , 1983, The Journal of pharmacology and experimental therapeutics.

[31]  R. W. Freeman,et al.  Effect of sulfhydryl-containing compounds on the antitumor effects of adriamycin. , 1980, Toxicology and applied pharmacology.

[32]  R. Newman,et al.  Amelioration of adriamycin and daunorubicin myocardial toxicity by adenosine. , 1981, Cancer research.

[33]  E. Mimnaugh.  Potentiation by reduced glutathione of adriamycin-stimulated lipid peroxidation in kidney microsomes. , 1986, Biochemical pharmacology.

[34]  N. Bachur,et al.  A general mechanism for microsomal activation of quinone anticancer agents to free radicals. , 1978, Cancer research.

[35]  G. Yee,et al.  The anticancer agent adriamycin can be actively cytotoxic without entering cells. , 1982, Science.

[36]  F. Muggia,et al.  Cardiotoxicity of anthracyclines. , 1984, European journal of cancer & clinical oncology.

[37]  H. Joenje,et al.  Effect of endogenous glutathione, superoxide dismutases, catalase, and glutathione peroxidase on adriamycin tolerance of Chinese hamster ovary cells. , 1988, Cancer research.

[38]  D. J. Reed,et al.  Protective role of the glutathione redox cycle against adriamycin-mediated toxicity in isolated hepatocytes. , 1981, Biochemical pharmacology.

[39]  J. Lankelma,et al.  The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells. , 1988, Cancer letters.

[40]  M. Scheulen,et al.  Acute adriamycin treatment of rats does not increase ethane expiration. , 1980, Research communications in chemical pathology and pharmacology.

[41]  C. Myers,et al.  Hydroxyl radical production and DNA damage induced by anthracycline‐iron complex , 1984, FEBS letters.

[42]  Paul J Thornalley,et al.  Free radical production from normal and adriamycin-treated rat cardiac sarcosomes. , 1985, Biochemical pharmacology.

[43]  A. Samuni,et al.  Reappraisal of the association between adriamycin and iron. , 1988, Cancer Research.

[44]  E. Mimnaugh,et al.  A possible role for membrane lipid peroxidation in anthracycline nephrotoxicity. , 1986, Biochemical pharmacology.

[45]  G. Batist,et al.  Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. , 1987, Biochemical pharmacology.

[46]  E. Mimnaugh,et al.  Differential effects of anthracycline drugs on rat heart and liver microsomal reduced nicotinamide adenine dinucleotide phosphate-dependent lipid peroxidation. , 1982, Cancer research.

[47]  Capen Cc,et al.  Subacute cardiotoxicity of adriamycin in the rat: biochemical and ultrastructural investigations. , 1977 .

[48]  J. Doroshow.  Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. , 1983, Cancer research.

[49]  J. Zweier,et al.  Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group. , 1986, Biochimica et biophysica acta.

[50]  J. Siegfried,et al.  Effects of anthracyclines on oxygenated and hypoxic tumor cells. , 1983, Cancer research.

[51]  M. Winker,et al.  Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. , 1985, Biochemical pharmacology.

[52]  T. Lampidis,et al.  Effects of adriamycin on rat heart cells in culture: increased accumulation and nucleoli fragmentation in cardiac muscle v. non-muscle cells. , 1981, Journal of molecular and cellular cardiology.

[53]  L. Liu,et al.  Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. , 1984, Cancer research.

[54]  A. Ramu,et al.  Oxygen radical detoxification enzymes in doxorubicin-sensitive and -resistant P388 murine leukemia cells. , 1984, Cancer research.

[55]  I. Mavelli,et al.  Prevention by fructose-1,6-bisphosphate of cardiac oxidative damage induced in mice by subchronic doxorubicin treatment. , 1987, Cancer research.

[56]  J. Noordhoek,et al.  The involvement of an oxidative mechanism in the adriamycin induced toxicity in neonatal rat heart cell cultures. , 1985, Research communications in chemical pathology and pharmacology.

[57]  P. Hochstein,et al.  Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. , 1977, Biochemical and biophysical research communications.

[58]  J. Noordhoek,et al.  Anthracycline-induced oxygen consumption and oxidative damage in rat liver microsomes are not necessarily coupled. A study with 8 structurally related anthracyclines. , 1985, Free radical research communications.

[59]  J. Gutteridge,et al.  Adriamycin-iron catalysed phospholipid peroxidation: a reaction not involving reduced adriamycin or hydroxyl radicals. , 1983, Biochemical pharmacology.

[60]  C. Winterbourn,et al.  Deoxyribose breakdown by the adriamycin semiquinone and H2O2: evidence for hydroxyl radical participation , 1982, FEBS letters.

[61]  C. Robson,et al.  Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. , 1988, The Journal of biological chemistry.

[62]  N. Mulder,et al.  Role of free radicals in an adriamycin-resistant human small cell lung cancer cell line. , 1987, Cancer research.

[63]  W. Haseltine,et al.  Reduction of adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. , 1981, The Journal of biological chemistry.

[64]  C. Simone,et al.  Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. , 1982, Biochemistry.

[65]  M. Israel,et al.  Relationship of adriamycin concentrations to the DNA lesions induced in hypoxic and euoxic L1210 cells. , 1983, Cancer research.

[66]  J. Gutteridge,et al.  Adriamycin‐dependent damage to deoxyribose: a reaction involving iron, hydroxyl and semiquinone free radicals , 1982 .

[67]  K. Handa,et al.  Electron spin resonance study on the mode of generation of free radicals of daunomycin, adriamycin, and carboquone in NAD(P)H-microsome system. , 1977, Gan.

[68]  N. Bachur,et al.  Comparative flavoprotein catalysis of anthracycline antibiotic. Reductive cleavage and oxygen consumption. , 1981, Molecular pharmacology.

[69]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[70]  S. Em,et al.  Lipid peroxidation as a mechanism of injury in cardiac myocytes. , 1982 .

[71]  R. I. Glazer,et al.  Cytokinetic and biochemical effects of 5-iminodaunorubicin in human colon carcinoma in culture. , 1982, Cancer research.

[72]  R D Olson,et al.  Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin. , 1980, The Journal of pharmacology and experimental therapeutics.

[73]  H. Pinedo,et al.  Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  H. W. Moore.  Bioactivation as a model for drug design bioreductive alkylation. , 1977, Science.

[75]  N. Bachur,et al.  Radical dimer rescue of toxicity and improved therapeutic index of adriamycin in tumor-bearing mice. , 1985, Cancer research.

[76]  L. Liu,et al.  Cleavage of DNA by mammalian DNA topoisomerase II. , 1983, The Journal of biological chemistry.

[77]  M. Green,et al.  Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line. , 1986, Cancer research.

[78]  J. Doroshow.  Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[79]  J. Doroshow,et al.  Mitochondrial NADH dehydrogenase‐catalyzed oxygen radical production by adriamycin, and the relative inactivity of 5‐iminodaunorubicin , 1983, FEBS letters.

[80]  J. Gutteridge,et al.  The role of superoxide and hydroxyl radicals in phospholipid peroxidation catalysed by iron salts , 1982, FEBS letters.

[81]  B. Halliwell,et al.  DNA damage by superoxide-generating systems in relation to the mechanism of action of the anti-tumour antibiotic adriamycin. , 1983, Biochimica et biophysica acta.

[82]  J. Doroshow,et al.  Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. , 1986, Biochemical and biophysical research communications.

[83]  Sugioka Katsuaki,et al.  Mechanism of phospholipid peroxidation induced by ferric ion-ADP-adriamycin-co-ordination complex. , 1982 .

[84]  S. Rajagopalan,et al.  Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. , 1988, Cancer research.

[85]  P. Riesz,et al.  Free radicals induced by adriamycin-sensitive and adriamycin-resistant cells: a spin-trapping study. , 1989, Biochemistry.

[86]  J. Lankelma,et al.  Glycolysis in P‐glycoprotein‐overexpressing human tumor cell lines Effects of resistance‐modifying agents , 1989, FEBS letters.

[87]  I. Mavelli,et al.  Differential cytotoxicity of daunomycin in tumour cells is related to glutathione-dependent hydrogen peroxide metabolism. , 1981, The Biochemical journal.

[88]  R. Friedman,et al.  Nuclear catalyzed antibiotic free radical formation. , 1982, Cancer research.

[89]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[90]  S. Barranco.  Cellular and molecular effects of adriamycin on dividing and nondividing cells. , 1984, Pharmacology & therapeutics.

[91]  C. Chignell,et al.  Binding mode of chemically activated semiquinone free radicals from quinone anticancer agents to DNA. , 1979, Chemico-biological interactions.

[92]  N. Tanaka,et al.  Alteration of membrane-associated enzymes in drug-resistant sublines of mouse lymphoblastoma L5178Y cells. , 1981, The Journal of antibiotics.

[93]  I. Ifrim,et al.  Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. , 1977, Science.

[94]  J. Doroshow,et al.  Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. , 1980, The Journal of clinical investigation.

[95]  R. Ozols,et al.  The anthracycline antineoplastic drugs. , 1981, The New England journal of medicine.

[96]  G Aubel-Sadron,et al.  Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. , 1984, Biochimie.

[97]  B. Halliwell,et al.  Doxorubicin-dependent lipid peroxidation at low partial pressures of O2. , 1985, Journal of free radicals in biology & medicine.

[98]  W. S. Thayer,et al.  Serum lipid peroxides in rats treated chronically with adriamycin. , 1984, Biochemical pharmacology.

[99]  F. Arcamone,et al.  Structure and Physicochemical Properties of Adriamycin (Doxorubicin) , 1972 .

[100]  G. Iliakis,et al.  Effect of sodium chloride concentration on adriamycin and N-trifluoroacetyladriamycin-14-valerate (AD32)-induced cell killing and DNA damage in Chinese hamster V79 cells. , 1987, Cancer research.

[101]  N. Bachur,et al.  Xanthine oxidase catalyzed reductive cleavage of anthracycline antibiotics and free radical formation. , 1980, Molecular pharmacology.

[102]  H. Joenje,et al.  Effect of artificial electron acceptors on the cytotoxicity of mitomycin C and doxorubicin in human lung tumor cells. , 1989, European journal of cancer & clinical oncology.

[103]  P. Vichi,et al.  Temperature dependence studies of adriamycin uptake and cytotoxicity. , 1987, Cancer research.

[104]  T. Lawrence.  Reduction of doxorubicin cytotoxicity by ouabain: correlation with topoisomerase-induced DNA strand breakage in human and hamster cells. , 1988, Cancer research.

[105]  W. Ross,et al.  Repair of deoxyribonucleic acid lesions caused by adriamycin and ellipticine. , 1982, Biochemical pharmacology.

[106]  E. Mimnaugh,et al.  Stimulation by adriamycin of rat heart and liver microsomal NADPH-dependent lipid peroxidation. , 1981, Biochemical pharmacology.

[107]  E. Mimnaugh,et al.  Adriamycin-enhanced membrane lipid peroxidation in isolated rat nuclei. , 1985, Cancer research.

[108]  F. Traganos,et al.  Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. , 1988, Cancer research.

[109]  J. Doroshow.  Effect of anthracycline antibiotics on oxygen radical formation in rat heart. , 1983, Cancer research.

[110]  D. J. Reed,et al.  Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by adriamycin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). , 1983, Biochemical pharmacology.